FALGUNI PATEL: Open Payments
NPI 1801567615 · FREDERICK, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$679 in 36 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $679
Food & beverage: $660Education: $19
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 9 | $180 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $149 |
| Lundbeck LLC | 5 | $109 |
| Teva Pharmaceuticals USA, Inc. | 5 | $104 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| ABBVIE INC. | 2 | $38 |
| OWP Pharmaceuticals, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
Products named: FANAPT, CAPLYTA, REXULTI, AUSTEDO XR, Auvelity, VRAYLAR, UZEDY, Subvenite.
Industry payments across MD — which companies pay providers there.
